

PRODUCT INFORMATION



Etodolac

Item No. 20833

CAS Registry No.: 41340-25-4

Formal Name: 1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid

Synonyms: AY 24236, (±)-Etodolac, NIH 9918, NSC 282126

MF: C₁₇H₂₁NO₃

FW: 287.4


Purity: ≥98%

UV/Vis.: λ_{max}: 224, 273 nm

Supplied as: A crystalline solid

Storage: Room temperature

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

Etodolac is supplied as a crystalline solid. A stock solution may be made by dissolving the etodolac in the solvent of choice. Etodolac is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of etodolac in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of etodolac can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of etodolac in PBS, pH 7.2, is approximately 0.25 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Etodolac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits both COX isoforms *in vitro*, with modest selectivity for COX-2 (IC₅₀s = 12 μM for COX-1 and 2.2 μM for COX-2 in a human whole blood assay).¹ Experimental evidence suggests that etodolac may have favorable tissue pharmacokinetics resulting in further COX-2 selectivity, indicated by favorable reduction in anti-inflammatory action with diminished gastric side effects.^{2,3}

References

1. Warner, T.D., Giuliano, F., Vojnovic, I., *et al.* Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full *in vitro* analysis. *Proc. Natl. Acad. Sci. USA* **96**, 7563-7568 (1999).
2. Dvornik, D.M. Tissue selective inhibition of prostaglandin biosynthesis by etodolac. *J. Rheumatol.* **24**, 40-50 (1997).
3. Riendeau, D., Percival, M.D., Brideau, C., *et al.* Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. *J. Pharmacol. Exp. Ther.* **296**, 558-566 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/14/2016

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM